title: Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b.
abstract: To verify the possible effect of IFN-beta treatment on auto antibodies development in multiple sclerosis (MS) we studied 69 MS patients before and during the treatment with IFN-beta 1b (n=35) and IFN-beta 1a (n=20) for 27 and 12 months respectively, and, as controls, 14 untreated MS patients. The serum, collected every 3 months from all the patients, was investigated for the presence of antinuclear (ANA), anti-smooth muscle (ASMA), anti-mitochondrial (AMA), anti-native DNA (nDNA) anti-cardiolipin (aCL), anti-parietal cells (APCA), anti-microsomal (AMC) and anti-tireoglobulin (ATG) antibodies. Among the IFN-beta 1b-treated MS patients an increase of the frequency and of the level of ANA, AMC and ATG was observed. ASMA and ANA antibodies were already present in about 45% of the MS patients before the treatment and fluctuated over the time. In one patient the treatment was interrupted after 6 months because of the occurrence of high ASMA level and of an autoimmune hepatitis. The data obtained in the smaller number of MS patients treated with IFN-beta 1a were very similar. No increase in aCL level was observed during both the IFN treatments. Our results indicate that the treatment with IFN-beta induces an increase of AMC and ATG antibodies in MS patients and confirm that, although rare, autoimmune diseases could be observed. The possible effect of these auto antibodies on the treatment efficacy and on MS clinical course need to be further investigated.
authors.affiliation: Laboratory of Biology, Don C. Gnocchi Foundation, IRCCS, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Speciale
authors.forename: M
authors.initials: M
authors.lastname: Saresella
authors.forename: D
authors.initials: D
authors.lastname: Caputo
authors.forename: S
authors.initials: S
authors.lastname: Ruzzante
authors.forename: R
authors.initials: R
authors.lastname: Mancuso
authors.forename: M G
authors.initials: MG
authors.lastname: Calvo
authors.forename: F R
authors.initials: FR
authors.lastname: Guerini
authors.forename: P
authors.initials: P
authors.lastname: Ferrante
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D000974:Antibodies, Antinuclear / Q000097:blood*; D001323:Autoantibodies / Q000276:immunology; D004247:DNA / Q000276:immunology; D005260:Female; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D008928:Mitochondria / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology*; D009130:Muscle, Smooth / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D017153:Antibodies, Anticardiolipin; D000974:Antibodies, Antinuclear; D001323:Autoantibodies; C051931:myasthenia gravis anti-skeletal muscle antibody; D000068576:Interferon beta-1b; D016899:Interferon-beta; D004247:DNA; D000068556:Interferon beta-1a